Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3847251 | 0.90 | — | — | |
| SCHEMBL3846173 | 0.87 | ESR2 (0.43) | LMNAHSD17B10ESR1ESR2HSD11B1 | |
| SCHEMBL5156005 | 0.86 | ESR1 (0.32) | LMNAHSD17B10ESR1ESR2HSD11B1 | |
| SCHEMBL3848400 | 0.82 | STS (0.31) | LMNAHSD17B10 | |
| SCHEMBL1829051 | 0.81 | ESR1 (0.44) | LMNAHSD17B10ESR1ESR2 | |
| SCHEMBL6028199 | 0.81 | ESR1 (0.44) | LMNAHSD17B10ESR1ESR2 | |
| SCHEMBL6027234 | 0.81 | ESR1 (0.44) | LMNAHSD17B10ESR1ESR2 | |
| SCHEMBL3854474 | 0.81 | ESR1 (0.32) | ESR1ESR2 | |
| SCHEMBL3854471 | 0.81 | ESR1 (0.32) | ESR1ESR2 | |
| SCHEMBL3847345 | 0.80 | RORC (0.33) | LMNAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2039702-A2 | Prodrugs erbeta-selective substances, method for their production and pharmaceutical compounds containing these compositions | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-25 | — | — | EP | disclosed |
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123500-A1 | Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds | CYP19A1, ESR2, HSD17B11 | LMNA 3785/4885HSD17B10 169/4885ESR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.